Belite Bio, Inc. completed a rolling submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for tinlarebant. This drug is intended for the treatment of Stargardt Disease Type 1. Belite Bio, Inc. is a biotechnology company focused on developing therapies for retinal diseases.